Mesoblast [ASX: MSB] has been granted a US patent through to 2019 for its Mesenchymal Precursor Cells [MPC], proprietary adult stem cells developed by Mesoblast and its sister company Angioblast Systems.

The patent ensures only Mesoblast and Angioblast can commercialise MPCs in the US.

MPCs were first identified in Australia, at the Hanson Institute in Adelaide. They are capable of repairing and regenerating a host of tissue types, including bone, cartilage, fat, blood vessels and heart muscle.